Sign In
Buy CERS
$2.66
-0.0400 (-1.48%)
At Close: Jun 03, 2026
Cerus Corporation (CERS) Q3 2024 Earnings Call Transcript
11:52pm, Wednesday, 30'th Oct 2024
Cerus Corporation (NASDAQ:CERS ) Q3 2024 Earnings Conference Call October 30, 2024 4:30 PM ET Company Participants Jessica Hanover - VP, Corporate Affairs Obi Greenman - President & CEO Vivek Jayarama
Cerus (CERS) Reports Q3 Loss, Tops Revenue Estimates
06:11pm, Wednesday, 30'th Oct 2024
Cerus (CERS) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to loss of $0.03 per share a year ago.
Cerus Corporation Announces Third Quarter 2024 Financial Results
04:00pm, Wednesday, 30'th Oct 2024
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced financial results for its third quarter and nine months ended September 30, 2024. Total revenue for the three and nin
Cerus Corporation to Release Third Quarter 2024 Financial Results on October 30, 2024
08:30am, Friday, 18'th Oct 2024
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its third quarter 2024 financial results will be released on Wednesday, October 30, 2024, after the close of the
Cerus Corporation Announces Workshop and Abstracts at the 2024 AABB Annual Meeting
08:30am, Friday, 18'th Oct 2024
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced a selection of abstracts to be presented at the 2024 Association for the Advancement of Blood & Biotherapies (AABB) A
Cerus Corporation Provides Updates on INTERCEPT Red Blood Cell Programs in the U.S. and Europe
04:00pm, Wednesday, 16'th Oct 2024
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq:CERS) today announced updates on the INTERCEPT red blood cell (RBC) programs in the U.S. and in Europe: U.S. – New $248 million BARDA cont
Cerus Corporation (CERS) Q2 2024 Earnings Call Transcript
08:29pm, Thursday, 01'st Aug 2024
Cerus Corporation (NASDAQ:CERS ) Q2 2024 Earnings Conference Call August 1, 2024 4:30 PM ET Company Participants Jessica Hanover - VP, Corporate Affairs Obi Greenman - President & CEO Vivek Jayaraman
Cerus (CERS) Reports Q2 Loss, Tops Revenue Estimates
06:11pm, Thursday, 01'st Aug 2024
Cerus (CERS) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.07 per share a year ago.
Cerus Corporation to Release Second Quarter 2024 Financial Results on August 1, 2024
08:30am, Thursday, 18'th Jul 2024
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its second quarter 2024 financial results will be released on Thursday, August 1, 2024, after the close of the s
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq:CERS) today announced a lunch symposium and selection of abstracts at the 38th International Congress of the International Society of Blood
Cerus Corporation Celebrates World Blood Donor Day 2024
08:30am, Friday, 14'th Jun 2024
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) is proud to announce its celebration of World Blood Donor Day 2024. In 2005, the World Health Assembly designated June 14 as World Bl
Cerus Corporation to Participate in 21st Annual Craig-Hallum Institutional Investor Conference
08:30am, Wednesday, 22'nd May 2024
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that Kevin Green, Cerus' chief financial officer, is scheduled to participate at the 21st Annual Craig-Hallum Institu
Cerus Corporation (CERS) Q1 2024 Earnings Call Transcript
07:37pm, Thursday, 02'nd May 2024
Cerus Corporation (NASDAQ:CERS ) Q1 2024 Results Conference Call May 2, 2024 4:30 PM ET Company Participants Jessica Hanover - Vice President of Corporate Affairs Obi Greenman - President and Chief Ex
Cerus Corporation to Release First Quarter 2024 Financial Results on May 2, 2024
08:30am, Thursday, 18'th Apr 2024
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its first quarter 2024 financial results will be released on Thursday, May 2, 2024, after the close of the stock
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced that the U.S. Food and Drug Administration (FDA) has granted approval of 12-month shelf life for INTERCEPT Platelet P
